JYJunpei Yamaguchi

Junpei Yamaguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Junpei Yamaguchi has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neoadjuvant Chemotherapy ( FOLFIRINOX or Gemcitabine With Nab‐Paclitaxel) for Borderline‐Resectable Pancreatic Cancer: Long‐Term Results of a Randomized Controlled Trial ( NUPAT ‐01)

    by Junpei Yamaguchi, Hideki Takami, Yukihiro Yokoyama, Tsutomu Fujii, Suguru Yamada, Hiroki Kawashima, Takuya Ishikawa, Osamu Maeda, Hiroshi Ogawa, Tomoki Ebata

    Background: Initial results of NUPAT‐01 suggest the feasibility of multidrug neoadjuvant chemotherapy for borderline‐resectable pancreatic cancer and favorable survival of patients, and we report on the long‐term results of this study. Methods: In this multicenter, phase II trial (NUPAT‐01), patients with borderline‐resectable pancreatic cancer were randomly assigned to receive neoadjuvant chemotherapy with either FOLFIRINOX (original regimen) or gemcitabine with nab‐paclitaxel (GEM/nab‐PTX) and underwent subsequent surgery if feasible. The primary endpoint was the R0 resection rate. Results: Fifty‐one eligible patients were randomly assigned to FOLFIRINOX ( n = 26) or GEM/nab‐PTX ( n = 25). Forty‐three patients underwent surgery, and R0 resection was achieved in 33 patients. An Intention‐to‐treat (ITT) analysis revealed a 3‐year overall survival of 51.0% and a 5‐year overall survival of 35.3% with a median survival time of 36.5 months. No significant difference between the FOLFIRINOX group and the GEM/nab‐PTX group was found in the ITT analysis or in patient survival after surgery. However, patients with a favorable response to chemotherapy had significantly better disease‐free survival. Conclusion: These results suggest no significant difference between the benefit of FOLFIRINOX and GEM/nab‐PTX as neoadjuvant chemotherapy for borderline‐resectable pancreatic cancer, and the survival of patients depends not on the regimen but on the response to chemotherapy.

  • Indocyanine Green–Guided Decision‐Making for Cervical Esophagogastric Anastomosis Using the Modified Collard Technique: Implementation and Temporal Stability in a Consecutive Cohort

    by Tetsuya Abe, Takahiro Hosoi, Eiji Higaki, Takuya Nagao, Kosuke Inada, Kotaro Ozaki, Byonggu An, Junpei Yamaguchi, Koji Komori, Seiji Ito

    Background: Anastomotic leakage (AL) remains a major complication after cervical esophagogastric anastomosis. Although indocyanine green (ICG) fluorescence imaging has been used to assess gastric conduit perfusion, its role in structured intraoperative decision‐making and the temporal stability of outcomes remain unclear. Methods: This single‐center retrospective study included 507 consecutive patients who underwent esophagectomy with cervical esophagogastric anastomosis using the modified Collard technique under a standardized ICG‐guided protocol. Intraoperative ICG imaging was used to identify poorly perfused distal conduit segments for exclusion. Temporal trends were evaluated using moving average and cumulative sum (CUSUM) analyses. Results: Anastomotic leakage occurred in 19 patients (3.75%), including clinically relevant leakage (grade ≥ III) in 13 (2.56%). Reoperation was required in one case, with no leakage‐related mortality. ICG assessment prompted additional proximal resection in 49.9% of evaluable patients, reflecting frequent detection of marginal distal perfusion; however, final anastomoses were consistently constructed within adequately perfused zones. Temporal analyses, including CUSUM, demonstrated sustained performance below a stringent 5% target rate throughout the study period. Conclusions: A standardized ICG‐guided intraoperative decision‐making strategy for cervical esophagogastric anastomosis using the modified Collard technique was associated with a low (3.75%) and temporally stable anastomotic leakage rate. Rather than serving as a binary perfusion test, ICG imaging functioned as a practical rule‐out tool to exclude clearly unsafe conduit segments. When embedded within a structured decision‐making framework, this approach enabled consistent implementation and durable reconstructive quality in routine clinical practice.


  • Open Access

    Phase II trial of gemcitabine plus nab-paclitaxel–based chemoradiotherapy for locally advanced pancreatic cancer (NUPAT-05): Survival outcomes and feasibility of conversion surgery

    by Hironori Yamada, Haruyoshi Tanaka, Suguru Yamada, Hideki Takami, Masamichi Hayashi, Nobuhiko Nakagawa, Keisuke Kurimoto, Yoshikuni Inokawa, Nobuyuki Watanabe, Takuya Ishikawa, et al.

    Introduction: Although chemoradiotherapy (CRT) has exhibited activity against locally advanced pancreatic cancer (LAPC), no standard regimen has been established. We previously completed a phase I trial of CRT with gemcitabine plus nab-paclitaxel (GnP) and established the recommended dose. This single-arm, phase II study evaluated the safety and efficacy of CRT incorporating GnP in patients with LAPC.Methods: Patients with LAPC received the NUPAT-05 trial protocol treatment (UMIN000028116). Conversion surgery (CS) was considered for patients who achieved favorable local disease control and tumor marker normalization. The primary endpoint was the 2-year overall survival (OS) rate, with a predefined threshold of 15%, and the co-primary feasibility endpoint was the CS rate. The secondary endpoints included OS, progression free survival (PFS), time to treatment failure (TTF), and adverse events.Results: Twenty-five patients were enrolled in the trial. The 2-year OS rate was 36.0% (95% confidence interval [CI] = 18.0–57.5), meeting the primary endpoint. The CS rate was 32.0% (95% CI = 14.9–53.5). The 2-year OS rate reached 75.0% (95% CI = 31.5–93.1) among patients who underwent CS. The median OS, PFS, and TTF were 20.8, 13.8, and 7.9 months, respectively. Postoperative major complications occurred in 37.5% of patients undergoing CS. Although adverse events (grade ≥ 3) occurred in 92.0% of patients, no treatment-related grade 5 events occurred.Conclusions: GnP-based CRT displayed encouraging clinical activity with manageable toxicity in patients with LAPC. Future studies are needed to validate the additional benefits of radiotherapy.

  • Open Access

    Differences in Right Hepatic Duct Length Among Left‐Sided Hepatectomies: Conventional Hepatectomy Versus Extended Hepatectomy Versus Trisectionectomy

    by Kota Sugiura, Mihoko Yamada, Takashi Mizuno, Shunsuke Onoe, Nobuyuki Watanabe, Shoji Kawakatsu, Junpei Yamaguchi, Masaki Sunagawa, Taisuke Baba, Tomoki Ebata

    Background: Left‐sided hepatectomy for perihilar cholangiocarcinoma includes conventional left hepatectomy (C‐LH; H1234‐B), extended left hepatectomy (E‐LH; H12345′8′‐B‐MHV), and left trisectionectomy (LT; H123458‐B). The anatomical characteristics of the resected length of the right hepatic duct (RHD) in E‐LH remain unclear. This study aimed to characterize the length of the RHD across procedures. Methods: Patients who underwent left‐sided hepatectomy for perihilar tumors between 2015 and 2023 were retrospectively reviewed. The shortest distance between the proximal bile duct stump and left hepatic duct orifice was measured on the resected specimens. The lengths and clinicopathological features of the procedures were compared. Results: In total, 205 patients were included: C‐LH ( n = 80), E‐LH ( n = 53), and LT ( n = 72). The length of the right anterior hepatic duct was longer in E‐LH than that in C‐LH (15.2 vs. 13.0 mm, p = 0.006). Similarly, the length of the right posterior hepatic duct increased stepwise from C‐LH to E‐LH and LT (13.3, 16.6, and 20.0 mm, respectively). Conclusions: E‐LH is an intermediate procedure between C‐LH and LT with respect to the resected length of the RHD. The additional bile duct length achieved by E‐LH is minimal, and this procedure should be selected primarily to secure the parenchymal margin rather than ductal clearance.

  • Influence of the Functional Reserve of the Remnant Liver on Major Hepatectomy Combined With Pancreatoduodenectomy

    by Takashi Mizuno, Shunsuke Onoe, Nobuyuki Watanabe, Mihoko Yamada, Shoji Kawakatsu, Junpei Yamaguchi, Masaki Sunagawa, Taisuke Baba, Tomoki Ebata

    Background/Purpose: Major hepatopancreatoduodenectomy (HPD) is associated with a high risk of postoperative mortality, often due to pancreatic fistula formation and liver failure. We evaluated the impact of the functional reserve of the remnant liver on postoperative pancreatic fistula (POPF) formation and mortality. Methods: Patients who underwent resection of ≥ 3 hepatic segments with pancreatoduodenectomy were retrospectively analyzed. The association of the future liver remnant‐to‐body weight ratio (FLR/BW) with POPF formation and mortality was assessed. With receiver operating characteristic (ROC) curve analysis, the optimal cutoff values were determined. Underlying pancreatic conditions were also examined. Results: POPFs occurred in 64% of 177 patients. The predictors of POPFs included a high BMI, low pancreatic CT attenuation, and small pancreatic duct diameter. The FLR/BW was not associated with POPF formation. Postoperative mortality occurred in 6% of patients, mostly due to Grade C postpancreatectomy hemorrhage. An FLR/BW < 0.8% was an independent predictor of mortality (OR 15.79); patients with a ratio below 0.8% had a 14% mortality rate. Conclusions: Poor remnant liver functional reserve is not associated with POPF formation but significantly increases mortality after major HPD. Ensuring sufficient liver reserve, perhaps through more proactive use of portal vein embolization or parenchyma‐sparing procedures, may improve outcomes.


  • Open Access

    Dedifferentiation-Dependent Regeneration of the Biliary Ductal Epithelium in Response to Hepatic Injury in TFF1-Deficient Mice

    by Taisuke Yamamoto, Junpei Yamaguchi, Toshio Kokuryo, Yukihiro Yokoyama, Takashi Mizuno, Shunsuke Onoe, Masaki Sunagawa, Taisuke Baba, Tomoki Ebata

    The mechanisms involved in the regeneration of biliary epithelial cells (BECs) after liver injury remain unclear. In this study, we employed KRT19CreERT/LSL-tdTomato (KT) mice and KT/TFF1KO mice to clarify the regeneration and cell fate of BECs via lineage tracing. Tamoxifen (TAM) was administered to the mice to label cytokeratin 19 (CK19)-positive BECs. The mice were subsequently fed a choline-deficient, ethionine-supplemented (CDE) diet for four weeks, after which the mouse livers were analyzed. Whereas the proportion of tdTomato+ cells in CK19-positive BECs decreased in the KT mice, it remained high in the KT/TFF1KO mice. Then, we analyzed hepatic progenitor cells (HPCs), the possible source of BECs. Although tdTomato-labeled HPCs were rarely found in the pretreatment mice, they were frequently found in the KT/TFF1KO mice after the CDE diet, suggesting the dedifferentiation of tdTomato-labeled BECs to HPCs. These results indicate not only that the loss of TFF1 accelerates the dedifferentiation of BECs into HPCs but also that HPCs are the source of BECs in TFF1KO mice. In addition, tdTomato-labeled HNF4α-positive hepatocytes were frequently found in the KT/TFF1KO mice, revealing the transdifferentiation of BECs to hepatocytes. The role of TFF1 as an inducer of biliary differentiation might be useful in the treatment of patients with hepatic or biliary dysfunction.

  • Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct

    by Shunsuke Onoe, Takashi Mizuno, Nobuyuki Watanabe, Shoji Kawakatsu, Junpei Yamaguchi, Taisuke Baba, Ryusei Yamamoto, Yoshie Shimoyama, Toshio Kokuryo, Tomoki Ebata

    Background: Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear. Methods: This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi‐quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2‐negative and HER2‐positive groups, respectively. Results: A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2‐positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2‐positive group. The HER2‐positive group demonstrated significantly worse overall survival than the HER2‐negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors. Conclusion: HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.


  • Reappraisal of carcinoma in situ residue at the bile duct margin: a single-center review of 681 patients with perihilar cholangiocarcinoma

    by Ryusei Yamamoto, Shunsuke Onoe, Takashi Mizuno, Nobuyuki Watanabe, Shoji Kawakatsu, Masaki Sunagawa, Junpei Yamaguchi, Atsushi Ogura, Taisuke Baba, Tsuyoshi Igami, et al.


  • Open Access

    Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer

    by Takanori Jinno, Junpei Yamaguchi, Atsushi Ogura, Toshio Kokuryo, Yukihiro Yokoyama, Masaki Sunagawa, Taisuke Baba, Yuki Murata, Tomoki Ebata

    Background/Aim: Recent studies suggest that PD-L1 expression in immune cells, rather than tumor cells, plays a key role in tumor immunity. Trefoil factor family 1 (TFF1) is a secreted protein expressed mainly by the gastrointestinal epithelium and is related to the development of malignant disease. This study investigated the effects of TFF1 on tumor immunity in a xenograft mouse model of colorectal cancer (CRC). Materials and Methods: MC38 cells were implanted in wild-type (WT) and TFF1KO mice, and the tumor micro-environment was investigated using immunohistochemistry. The circulating immune cells were analyzed using flow cytometry. Results: Tumor growth was suppressed in TFF1KO mice. In the tumor microenvironment, CD8- and CD4-positive T cells and CD11c-positive dendritic cells (DCs) were frequently found in TFF1KO mice. When an immune checkpoint inhibitor was administered to these mice, almost half of the tumors in TFF1KO mice showed a complete response. The number of circulating PD-L1/DCs was markedly associated with tumor volume, with TFF1 deletion accelerating this effect and its injection decreasing it. These findings indicate that loss of TFF1 activates tumor immunity via frequent T-cell priming by DCs, and eventually suppresses tumor growth in CRC. In addition, the number of circulating PD-L1/DCs was identified as a predictive marker of checkpoint-inhibiting therapy efficacy. Conclusion: Loss of TFF1 resulted in accelerated immune response to colorectal cancer. Further studies are needed to investigate the precise mechanisms of TFF1 in immunotolerance and develop a novel TFF1-inhibiting immunotherapeutic strategy for CRC.

  • Open Access

    Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer

    by Junpei Yamaguchi, Toshio Kokuryo, Yukihiro Yokoyama, Shunsuke Oishi, Masaki Sunagawa, Takashi Mizuno, Shunsuke Onoe, Nobuyuki Watanabe, Atsushi Ogura, Tomoki Ebata

    Background and Aims: Pancreatic cancer is one of the most lethal malignancies, partly due to resistance to conventional chemotherapy. The chemoresistance of malignant tumors is associated with epithelial‐mesenchymal transition (EMT) and the stemness of cancer cells. The aim of this study is to investigate the availability and functional mechanisms of trefoil factor family 1 (TFF1), a tumor‐suppressive protein in pancreatic carcinogenesis, to treat pancreatic cancer.Methods: To investigate the role of endogenous TFF1 in human and mice, specimens of human pancreatic cancer and genetically engineered mouse model of pancreatic cancer (KPC/TFF1KO; Pdx1‐Cre/LSL‐KRASG12D/LSL‐p53R172H/TFF1−/−) were analyzed by immunohistochemistry (IHC). To explore the efficacy of extracellular administration of TFF1, recombinant and chemically synthesized TFF1 were administered to pancreatic cancer cell lines, a xenograft mouse model and a transgenic mouse model.Results: The deficiency of TFF1 was associated with increased EMT of cancer cells in mouse models of pancreatic cancer, KPC. The expression of TFF1 in cancer cells was associated with better survival rate of the patients who underwent chemotherapy, and loss of TFF1 deteriorated the benefit of gemcitabine in KPC mice. Extracellular administration of TFF1 inhibited gemcitabine‐induced EMT, Wnt pathway activation and cancer stemness, eventually increased apoptosis of pancreatic cancer cells in vitro. In vivo, combined treatment of gemcitabine and subcutaneous administration of TFF1 arrested tumor growth in xenograft mouse model and resulted in the better survival of KPC mice by inhibiting EMT and cancer stemness.Conclusion: These results indicate that TFF1 can contribute to establishing a novel strategy to treat pancreatic cancer patients by enhancing chemosensitivity.